Because gremlin-1 acts as a mediator of BMPRII pathway inhibition by endothelin66, gremlin-1 modulation could also be a potential point of mechanistic convergence between therapeutic effects of ActRIIA-Fc and those of endothelin receptor antagonists in patients with PAH. This evidence concerns the gene BMPR2 and pulmonary arterial hypertension.